摘要:
This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.
摘要:
This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formula I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I-III and at least one carrier, diluent or excipient.
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为O,包括立体异构体,互变异构体,代谢物及其药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
A data processing method for operating a sample program and a related application programming interface comprises executing instructions of the sample program, and, for each specific instruction consisting of a call to the related application programming interface, accessing information embedded in the application programming interface relating to the specific instruction and presenting the information relating to the specific instruction.
摘要:
Techniques and systems for modifying a virtual machine functionality. Archive files each including at least a class files are received. The archive files are stored within the virtual machine. The virtual machine runs on a host system and neither the virtual machine nor the host system are restarted in response to the receiving or storing of the archive files. Files of the host system are scanned to find class files that are not included in a class path for the virtual machine. The class files are copied to a class path for the virtual machine. Neither the virtual machine nor the host system are restarted in response to the copying of the class files. The classes corresponding to the class files are registered in the virtual machine in response to the copying of the class files to the class path. Neither the virtual machine nor the host system are restarted in response to the registration of the classes.
摘要:
A monitoring device for monitoring treatment of the item that includes a sensor for sensing a condition relating to the treatment of the item, a memory arranged to store sensor data, and a communication interface for generating a wireless signal for transmitting the data. The device also includes a detector for detecting a predetermined event relating to the condition. The device is triggered to switch from a low power mode to a high power mode for a finite time period following detection of the predetermined event, and to switch from the high power mode to the low power mode upon expiry of the time period. In the high power mode the device is configured so as to read sensor data at an increased rate in order to gather sensor data or to send a communication signal at an increased rate for establishing a connection for transmitting data.
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为O,包括立体异构体,互变异构体,代谢物及其药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为0,包括立体异构体,互变异构体,代谢物和药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
摘要翻译:本发明提供下式的化合物或其药学上可接受的盐,溶剂合物或前药,其中p,Ar,R 1,R 2,R 3, R SUP,R,B,R,C,R,D, / SUP>。 还提供药物组合物,使用方法和制备化合物的方法。